Lumos Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lumos Pharma, Inc.
Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone
Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Rare Pediatric Disease Voucher Program Gains Temporary Extension From House Committee
US incentive program would gain only four more years, despite calls for a permanent extension.
Rare Pediatric Priority Review Voucher Program Seems Headed For Short-Term Renewal
Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.
- Large Molecule
- Other Names / Subsidiaries
- BioProtection Systems Corporation (BPS)
- BlueLink Pharmaceuticals
- NewLink Genetics
- NewLink Genetics Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.